ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0484

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis

Lien Moreel1, Albrecht Betrains1, Geert Molenberghs2, Steven Vanderschueren1 and Daniel Blockmans1, 1University Hospitals Leuven, KU Leuven, Leuven, Belgium, 2KU Leuven, Leuven, Belgium

Meeting: ACR Convergence 2022

Keywords: giant cell arteritis, meta-analysis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The aim of this study was to estimate the timing of relapse, the prevalence of multiple relapses and the predictors of relapse in patients with giant cell arteritis (GCA).

Methods: PubMed, Embase and Cochrane databases were searched from inception till November, 30 2021. Outcome measures include cumulative relapse rate (CRR) of first relapse at year 1, 2, and 5 after treatment initiation, CRR of second and third relapse and predictors of relapse. A random-effects model was used.

Results: Thirty studies (2595 patients) were included for timing of relapse, 16 studies (1947 patients) for prevalence of multiple relapses and 40 studies (4213 patients) for predictors of relapse. One-year, 2-year and 5-year CRRs were 32.0% [95% CI 22.4 – 43.6%], 44.3% [95% CI 30.5 – 59.1%], and 46.6% [95% CI 27.2 – 67.1%], respectively. The duration of scheduled glucocorticoid therapy was negatively associated with the 1-year CRR (p = 0.05). CRR of second and third relapse were 29.6% [95% CI 20.6 – 40.0] and 16.9% [95% CI 8.0 – 32.5%], respectively. Female sex (OR 1.43) and large vessel involvement (OR 2.04) were predictors of relapse.

Conclusion: Relapse occurred in almost half of GCA patients mainly during the first two years after diagnosis. One in three patients had multiple relapses. The optimal glucocorticoid tapering schedule, which seeks a balance between the lowest relapse risk and the shortest glucocorticoid duration, needs to be determined in future studies. Longer scheduled glucocorticoid therapy or early introduction of glucocorticoid-sparing agents may be warranted in female patients and patients with large vessel involvement.

Supporting image 1

Figure 1: Forest plot of the cumulative relapse rate of first relapse at year 1, 2 and 5 after treatment initiation.

Supporting image 2

Figure 2: Forest plot of the cumulative relapse rate of second and third relapse

Supporting image 3

Figure 3: Forest plot of predictors of relapse A. Binary predictors B. Continuous predictors


Disclosures: L. Moreel, None; A. Betrains, None; G. Molenberghs, None; S. Vanderschueren, None; D. Blockmans, None.

To cite this abstract in AMA style:

Moreel L, Betrains A, Molenberghs G, Vanderschueren S, Blockmans D. Epidemiology and Predictors of Relapse in Giant Cell Arteritis: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/epidemiology-and-predictors-of-relapse-in-giant-cell-arteritis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-predictors-of-relapse-in-giant-cell-arteritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology